Inicio>>Signaling Pathways>> GPCR/G protein>> FFAR1 (GPR40)>>GW9508

GW9508

Catalog No.GC12401

GW9508 es un agonista potente y selectivo de los receptores acoplados a proteÍna G FFA1 (GPR40) y GPR120 con pEC50 de 7,32 y 5,46, respectivamente.

Products are for research use only. Not for human use. We do not sell to patients.

GW9508 Chemical Structure

Cas No.: 885101-89-3

Tamaño Precio Disponibilidad Cantidad
10mM (in 1mL DMSO)
36,00 $
Disponible
10mg
31,00 $
Disponible
50mg
144,00 $
Disponible
100mg
223,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

GW9508 is a selective agonist of GPR40 and 120 with pEC50 value of 7.32 ± 0.03 and 5.46 ± 0.09, respectively [1].
GPR40/120 belongs to G protein-coupled receptors (GPCRs) family and is activated by free fatty acids. Mucosal inflammation induced the overexpression of GPR40, GPR120, and several inflammatory cytokines, with correlations between ileal concentrations of tumor necrosis factor (TNF)-α and GPR expression levels [2] [3].
GW9508 is a GPR40/120 agonist and is different from the reported GPR40/120 agonist GW1100. When tested with HEK-293 (human embryonic kidney) cells expressing GPR40 or GRP120, GW9508 treatment increased intracellular Ca2+ concentration via activating GPR40/120 in a dose-dependent manner [1]. In rat pancreaticβ-cells, GW9508 treatment activated KATP channels which inhibited GSIS through agonist of GPR40 and GPR120 [4]. When tested with TNF-α treated rat L cells, administration of GW9508 increased the expression of GLP-2 via activating GPR40 and 120 [2].
References:
[1].Briscoe, C.P., et al., Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. Br J Pharmacol, 2006. 148(5): p. 619-28.
[2].Tsukahara, T., et al., Tumor necrosis factor alpha decreases glucagon-like peptide-2 expression by up-regulating G-protein-coupled receptor 120 in Crohn disease. Am J Pathol, 2015. 185(1): p. 185-96.
[3].Habib, A.M., et al., Co-localisation and secretion of glucagon-like peptide 1 and peptide YY from primary cultured human L cells. Diabetologia, 2013. 56(6): p. 1413-6.
[4].Zhao, Y.F., et al., GW9508 inhibits insulin secretion by activating ATP-sensitive potassium channels in rat pancreatic beta-cells. J Mol Endocrinol, 2013. 51(1): p. 69-77.

Reseñas

Review for GW9508

Average Rating: 5 ★★★★★ (Based on Reviews and 23 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for GW9508

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.